SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is facing extreme volatility after a Muddy Waters research report alleged accounting irregularities and improper debt classification, leading to a massive volume spike and price fluctuations. While short sellers are leveraging these claims to profit, the company has officially pushed back, dismissing the report as factually inaccurate and announcing its intention to pursue legal action, further bolstered by CEO Anthony Noto continuing to increase his own position in the stock.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is undergoing a intense period of volatility as market participants debate whether the stock is a fundamental AI play or a parabolic bubble nearing a rug pull. While many in the community are focused on a potential super-cycle driven by memory chip shortages and institutional accumulation, others are aggressively shorting the stock, citing extreme valuation concerns and technical indicators that mirror previous market blow-offs.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. (SWMR) is seeing intense trading volume and volatility following a volatile IPO, with investors speculating on the potential of its combat-tested drone autonomy software. The community is actively debating the company's valuation against its early-stage financials while highlighting strong sector interest in defense technology and the potential for a massive short-term squeeze.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as investors aggressively position ahead of its quarterly earnings report, driven by optimistic sentiment surrounding HBM4 memory demand and its strategic role in Nvidias new AI platforms. The community remains deeply divided, with bulls highlighting a multi-year memory "super-cycle" and low forward valuation, while skeptical bears warn that the stock has become overextended and potentially vulnerable to a "sell the news" correction.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing heightened community engagement as investors debate its regulatory status as a digital commodity, with many pointing to potential long-term network utility and institutional adoption. While some participants are aggressively accumulating through staking and DCA strategies, others are expressing frustration over stagnant price action and are closely monitoring key technical support levels to gauge the next move.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is trending as investors digest a series of strategic acquisitions, including the recent purchase of Indo Earth Moving, which bolsters the company's position as a prime defense contractor. The community is actively debating the company's aggressive acquisition strategy, with bulls emphasizing the massive backlog and drone-centric market opportunities while bears express concerns over potential stock dilution and the operational complexity of integrating these new business units.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is experiencing a significant surge in trading volume and upward price momentum as investors speculate on potential buyout interest and anticipate the upcoming earnings call. The community is actively discussing the stock's growth potential and best-in-class product profile, with many anticipating that institutional accumulation could drive the share price higher following recent technical breakouts.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is experiencing high volatility as traders react to persistent geopolitical tensions in the Strait of Hormuz and conflicting reports regarding the potential for an international tanker escort coalition. Community sentiment is deeply polarized, with many market participants debating whether the rally is a structural response to supply disruptions or a manipulated move driven by government intervention and treasury-led shorting.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is seeing heightened market attention as traders weigh its aggressive capital expenditure toward AI infrastructure against the long-term potential of its Gemini model and autonomous vehicle division. Investors are actively debating whether these high-cost AI initiatives will deliver proportional revenue growth or if the heavy spending cycle will continue to pressure margins in a competitive landscape.

DocuSign, Inc. engages in the provision of cloud-based electronic signature solutions, which helps companies and individuals securely collect information, automate data workflows, and sign anything. The firm automates manual and paper-based processes allowing users to manage all aspects of documented business transactions including identity management, authentication, digital signature, forms and data collection, collaboration, workflow automation, and storage. Its products include eSignature, CLM, Gen for Salesforce, Document Generation, Standards-Based Signatures, Notary and Web Forms. The company was founded by Thomas H. Gonser and Court Lorenzini in 2003 and is headquartered in San Francisco, CA.

DocuSign Inc

DocuSign is experiencing heightened investor interest driven by a significant spike in trading volume and optimism surrounding its pivot toward AI-integrated Intelligent Agreement Management (IAM). Market participants are actively debating the company's long-term competitive moat against AI-driven disruption, while closely monitoring share repurchase activity and potential acquisition speculation as key catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lantheus Holdings, Inc. (LNTH) said on Tuesday that the U.S. Food and Drug Administration has extended its review of LNTH-2501 by three months.Shares of the company slipped marginally after hours at the time of writing.<h2 class="st-heading-2">Why The Delay?</h2>The agency is now slated to decide on the radiopharmaceutical-focused company’s application seeking approval for the diagnostic kit by June 29. The extended deadline is expected to give the agency additional time to review and consider further manufacturing related information submitted by Lantheus, it said.The extension, however, is not related to the efficacy or safety data of LNTH-2501, a radioactive diagnostic kit for for use with positron emission tomography (PET) for detecting somatostatin receptor positive neuroendocrine tumors in adults as well as pediatric patients, the company added.LNTH-2501 is not available in the U.S. yet.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around LNTH stock stayed within the ‘extremely bearish’ territory while message volume fell from ‘high’ to ‘normal’ levels.According to data from Koyfin, the 12-month average price target on the stock is at $91, representing a potential upside of about 13%. Of the 13 analysts covering the stock, 11 rate it ‘Buy’ or higher while two rate it a ‘Hold.’Earlier this month, Lantheus announced that the FDA approved its PYLARIFY TruVu injection. The injection is indicated for imaging certain lesions in men with prostate cancer, the second most common form of cancer affecting men in the U.S. It is now expected to be commercially available in the fourth quarter of 2026.<a href="https://stocktwits.com/symbol/LNTH">LNTH stock</a> has slipped 22% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/lulu-shares-fall-despite-board-reshuffle-as-2026-outlook-misses-street-expectations/cZ3EZeyRIXz">LULU Shares Fall Despite Board Reshuffle As 2026 Outlook Misses Street Expectations</a>Get updates to this developing story directly on Stocktwits.

In this photo illustration, the Lantheus Holdings logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Lantheus Says FDA Pushed Deadline For Reviewing Its Tumor Diagnostic Kit Application

The agency is now slated to decide on the company’s application seeking approval for the diagnostic kit by June 29.

Equity

The agency is now slated to decide on the company’s application seeking approval for the diagnostic kit by June 29.


Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Average Recommendation of "Moderate Buy" by Analysts

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten ratings firms that are currently covering the stock, MarketBeat Ratings reports...

Lantheus (NASDAQ:LNTH) Lowered to Buy Rating by Wall Street Zen

Wall Street Zen lowered shares of Lantheus from a "strong-buy" rating to a "buy" rating in a research note on Sunday...

Portolan Capital Management LLC Purchases 42,731 Shares of Lantheus Holdings, Inc. $LNTH

Portolan Capital Management LLC lifted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 16.8% in the third quarter, according to the company in its most recent disclosure with...

Why Lantheus Holdings Stock Popped by Almost 12% Last Month

Key PointsAlthough its adjusted net income dipped, it handily beat analyst expectations on both the top and bottom lines...

Lantheus (NASDAQ:LNTH) Trading 7.2% Higher - Time to Buy?

Lantheus (NASDAQ:LNTH) Trading 7.2% Higher - Here's Why...

Teachers Retirement System of The State of Kentucky Reduces Stake in Lantheus Holdings, Inc. $LNTH

Teachers Retirement System of The State of Kentucky cut its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 49.0% during the third quarter, according to the company in its...

Wall Street Zen Upgrades Lantheus (NASDAQ:LNTH) to Strong-Buy

Wall Street Zen raised Lantheus from a "hold" rating to a "strong-buy" rating in a report on Saturday...

American Century Companies Inc. Sells 341,642 Shares of Lantheus Holdings, Inc. $LNTH

American Century Companies Inc. lowered its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 32.1% in the third quarter, according to the company in its most recent 13F...

<ul class="summary-bullets"><li>The injection is indicated for imaging certain lesions in men with prostate cancer, the second most common form of cancer affecting men in the U.S.</li><li>The new formulation has the same diagnostic properties and is expected to offer similar safety and effectiveness as formerly approved Pylarify.</li><li>The company noted that the new formulation supports more efficient manufacturing and distribution which are expected to increase batch sizes, improving supply flexibility.</li></ul>&nbsp;Shares of Lantheus Holdings, Inc. (LNTH) rose as much as 5% after hours on Friday after the company announced that the U.S. Food and Drug Administration has approved its PYLARIFY TruVu injection.The injection is indicated for imaging certain lesions in men with prostate cancer, the second most common form of cancer affecting men in the U.S. It is now expected to be commercially available in the fourth quarter of 2026.<h2 class="st-heading-2">About The Newly Approved Injection</h2>PYLARIFY TruVu is a new formulation of the company’s F 18 prostate-specific membrane antigen-targeted PET imaging agent. The new formulation has the same diagnostic properties and is expected to offer similar safety and effectiveness as formerly approved Pylarify.“The availability of PYLARIFY TruVu addresses a key need identified by clinicians – greater access to our market-leading formulation,” CEO Mary Anne Heino <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/03/06/3251298/0/en/Lantheus-Announces-FDA-Approval-of-PYLARIFY-TruVu-piflufolastat-F-18-Injection.html">said</a>. The company also noted that the new formulation supports more efficient manufacturing and distribution which are expected to increase batch sizes, improving supply flexibility.Lantheus said that the new injection would be rolled out in a way that it allows customers to transition from Pylarify to the new formulation with minimal disruption.Pylarify was approved in May 2021 and more than 760,000 people with prostate cancer have received scans with it since, the company noted.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around LNTH rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘normal’ levels.<a href="https://stocktwits.com/symbol/LNTH">LNTH stock</a> has declined 28% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nike-300-million-charge-announcement-indicates-intent-to-exit-converse-says-analyst/cZdLBK2RI4d">Nike’s $300M Charge Announcement Indicates Intent To Exit Converse, Says Analyst</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is LNTH Stock Up After Hours?

Lantheus said that the FDA approved its PYLARIFY TruVu injection. 

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America. The company was founded in 1956 and is headquartered in Bedford, MA.

LNTH
Lantheus Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest LNTH News

LNTHLantheus Holdings Inc